The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Effectiveness of First‐Line Treatment With Recombinant Interleukin‐1 Receptor Antagonist in Steroid‐Naive Patients With New‐Onset Systemic Juvenile Idiopathic Arthritis: Results of a Prospective Cohort Study
Abstract
Objective: To conduct a prospective cohort study using anakinra, a recombinant IL‐1 receptor antagonist (IL‐1Ra), as first‐line therapy in patients with new‐onset systemic juvenile idiopathic arthritis (JIA). Methods: Therapy with recombinant IL‐1Ra (2 mg/kg) was initiated in 20 patients who fulfilled the International League of Associations for Rheumatology criteria for systemic JIA, before systemic steroid treatment was administered. Patients were monitored clinically and immunologically. The protocol contained a stop strategy for patients who met at least the adapted American College of Rheumatology 90% criteria for improvement in JIA (ACR Pediatric 90 [ACR Pedi 90]) after 3 months. Results: We included consecutive patients with new‐onset systemic JIA. The mean followup period was 32 months (range 12–54 months). At the 3‐month time point, 85% of the patients showed an adapted ACR Pedi 90 response or had inactive disease; 75% of the patients achieved this response while receiving recombinant IL‐1Ra alone. After 1 year, 17 of the 20 patients met the criteria for clinically inactive disease, and 13 of these patients met these criteria while receiving monotherapy with recombinant IL‐1Ra. However, because of persistent disease activity, 7 of the 20 patients required additional therapy besides recombinant IL‐1Ra. According to our stop strategy, 73% of patients with at least an adapted ACR Pedi 90 response at 3 months could stop recombinant IL‐1Ra treatment within 1 year. After 2 years, 12 (86%) of 14 patients met the criteria for disease remission, either while receiving (n = 4) or not receiving (n = 8) medication. After 3 years, 10 (91%) of 11 patients met the criteria for disease remission, either while receiving (n = 2) or not receiving (n = 8) medication. Conclusion: This is the first prospective study in which recombinant IL‐1Ra was used as first‐line therapy in patients with systemic JIA. We observed excellent responses in nearly all patients within 3 months. In the majority of responding patients, treatment with recombinant IL‐1Ra could be stopped within 1 year, with remission being preserved during followup. In approximately one‐third of patients, concomitant therapy was required for maintenance of clinical response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Petty, R. E., Southwood, T. R. E., Manners, P. J., Baum, J., Glass, D. N., Goldenberg, J., He, X.-H., Maldonado-Cocco, J. A., Orozco-Alcalá, J., Prieur, A., et al. (2004) · PubMed · Cited by 4,176
Preliminary definition of improvement in juvenile arthritis
Giannini, E. H., Ruperto, N., Ravelli, A., Lovell, D. J., Felson, D. T., & Martini, A. (1997) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199707)40:7<1202::aid-art3>3.0.co;2-r · Cited by 1,047
Pascual, V., Allantaz, F., Arce, E., Punaro, M., & Banchereau, J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050473 · Cited by 922
Beukelman, T., Patkar, N. M., Saag, K. G., Tolleson‐Rinehart, S., Cron, R. Q., DeWitt, E. M., Ilowite, N. T., Kimura, Y., Laxer, R. M., Lovell, D. J., et al. (2011) · Arthritis Care & Research · doi:10.1002/acr.20460 · Cited by 834
Prakken, B., Albani, S., & Martini, A. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60244-4 · Cited by 771
Self-citationRandomized trial of tocilizumab in systemic juvenile idiopathic arthritis
De Benedetti, F., Brunner, H. I., Ruperto, N., Kenwright, A., Wright, S., Calvo, I., Cuttica, R., Ravelli, A., Schneider, R., Woo, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112802 · Cited by 763
Self-citationTwo Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis
Ruperto, N., Brunner, H. I., Quartier, P., Constantin, T., Wulffraat, N., Horneff, G., Brik, R., McCann, L., Kasapcopur, O., Rutkowska-Sak, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205099 · Cited by 713
Self-citationPreliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis.
Wallace, C. A., Ruperto, N., & Giannini, E. H. (2004) · PubMed · Cited by 623
Quartier, P., Allantaz, F., Cimaz, R., Pillet, P., Messiaen, C., Bardin, C., Bossuyt, X., Boutten, A., Bienvenu, J., Duquesne, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.134254 · Cited by 558
Nigrovic, P. A., Mannion, M., Prince, F. H. M., Zeft, A., Rabinovich, C. E., van Rossum, M. A. J., Cortis, E., Pardeo, M., Miettunen, P. M., Janow, G., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30128 · Cited by 463
Lequerré, T., Quartier, P., Rosellini, D., Alaoui, F., De Bandt, M., Mejjad, O., Kone-Paut, I., Michel, M., Dernis, E., Khellaf, M., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.076034 · Cited by 406
Gattorno, M., Piccini, A., Lasigliè, D., Tassi, S., Brisca, G., Carta, S., Delfino, L., Ferlito, F., Pelagatti, M. A., Caroli, F., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23437 · Cited by 382
de Benedetti, F., Massa, M., Robbioni, P., Ravelli, A., Burgio, G. R., & Martini, A. (1991) · Arthritis & Rheumatism · doi:10.1002/art.1780340912 · Cited by 358
de Jager, W., Hoppenreijs, E. P. A. H., Wulffraat, N. M., Wedderburn, L. R., Kuis, W., & Prakken, B. J. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.061853 · Cited by 347
Self-citationMacrophage activation syndrome
Ravelli, A. (2002) · Current Opinion in Rheumatology · doi:10.1097/00002281-200209000-00012 · Cited by 340
Proinflammatory S100 proteins in arthritis and autoimmune disease
Foell, D., & Roth, J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20631 · Cited by 334
Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions
Mellins, E. D., Macaubas, C., & Grom, A. A. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.68 · Cited by 330
The German etanercept registry for treatment of juvenile idiopathic arthritis
Horneff, G., Schmeling, H., Biedermann, T., Foeldvari, I., Ganser, G., Girschick, H. J., Hospach, T., Huppertz, H. I., Keitzer, R., Küster, R. M., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.014886 · Cited by 318
Grom, A. A., Villanueva, J., Lee, S., Goldmuntz, E. A., Passo, M. H., & Filipovich, A. (2003) · The Journal of Pediatrics · doi:10.1067/mpd.2003.110 · Cited by 284
Horneff, G., De Bock, F., Foeldvari, I., Girschick, H. J., Michels, H., Moebius, D., & Schmeling, H. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.087593 · Cited by 277
Shimizu, M., Yokoyama, T., Yamada, K., Kaneda, H., Wada, H., Wada, T., Toma, T., Ohta, K., Kasahara, Y., & Yachie, A. (2010) · Rheumatology · doi:10.1093/rheumatology/keq133 · Cited by 255
Villanueva, J., Lee, S., Giannini, E. H., Graham, T. B., Passo, M. H., Filipovich, A., & Grom, A. A. (2004) · Arthritis Res Ther · doi:10.1186/ar1453 · Cited by 243
De Benedetti, F., Massa, M., Pignatti, P., Albani, S., Novick, D., & Martini, A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117206 · Cited by 234
Vastert, S. J., van Wijk, R., D’Urbano, L. E., de Vooght, K. M. K., de Jager, W., Ravelli, A., Magni-Manzoni, S., Insalaco, A., Cortis, E., van Solinge, W. W., et al. (2010) · Rheumatology · doi:10.1093/rheumatology/kep418 · Cited by 231
Self-citationGrom, A. A. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20198 · Cited by 208
Ruperto, N., Quartier, P., Wulffraat, N., Woo, P., Ravelli, A., Mouy, R., Bader‐Meunier, B., Vastert, S. J., Noseda, E., D'Ambrosio, D., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33342 · Cited by 196
Self-citationFrosch, M., Ahlmann, M., Vogl, T., Wittkowski, H., Wulffraat, N., Foell, D., & Roth, J. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24349 · Cited by 190
Self-citationZhang, K., Biroschak, J., Glass, D. N., Thompson, S. D., Finkel, T., Passo, M. H., Binstadt, B. A., Filipovich, A., & Grom, A. A. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23734 · Cited by 182
Kimura, Y., Weiss, J. E., Haroldson, K. L., Lee, T., Punaro, M., Oliveira, S., Rabinovich, E., Riebschleger, M., Antón, J., Blier, P. R., et al. (2013) · Arthritis Care & Research · doi:10.1002/acr.21889 · Cited by 173
Self-citationHolzinger, D., Frosch, M., Kastrup, A., Prince, F. H. M., Otten, M. H., Van Suijlekom-Smit, L. W. A., Cate, R. T., Hoppenreijs, E. P. A. H., Hansmann, S., Moncrieffe, H., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200598 · Cited by 163
Self-citationde Jager, W., Vastert, S. J., Beekman, J. M., Wulffraat, N. M., Kuis, W., Coffer, P. J., & Prakken, B. J. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24750 · Cited by 158
Self-citationSystemic juvenile idiopathic arthritis
Martini, A. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.07.022 · Cited by 154
Lomater, C., Gerloni, V., Gattinara, M. V., Mazzotti, J., Cimaz, R., & Fantini, F. (2000) · PubMed · Cited by 154
Systemic JIA: new developments in the understanding of the pathophysiology and therapy
Vastert, S. J., Kuis, W., & Grom, A. A. (2009) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2009.08.003 · Cited by 143
Self-citationWulffraat, N. M. (2003) · British journal of rheumatology · doi:10.1093/rheumatology/keg074 · Cited by 140
Self-citationExpression of myeloid‐related proteins 8 and 14 in systemic‐onset juvenile rheumatoid arthritis
Frosch, M., Vogl, T., Seeliger, S., Wulffraat, N. M., Kuis, W., Viemann, D., Foell, D., Sorg, C., Sunderkötter, C. H., & Roth, J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11177 · Cited by 136
Self-citationSystemic juvenile idiopathic arthritis: diagnosis, management, and outcome
Woo, P. M. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0084 · Cited by 133
Shimizu, M., Nakagishi, Y., & Yachie, A. (2013) · Cytokine · doi:10.1016/j.cyto.2012.11.025 · Cited by 128
Macrophage activation syndrome in systemic juvenile rheumatoid arthritis
Grom, A. A., & Passo, M. H. (1996) · The Journal of Pediatrics · doi:10.1016/s0022-3476(96)70140-3 · Cited by 105
Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis?
Ramanan, A. V., & Grom, A. (2005) · Rheumatology · doi:10.1093/rheumatology/keh710 · Cited by 92
New insights in systemic juvenile idiopathic arthritis--from pathophysiology to treatment
Frosch, M., & Roth, J. (2007) · Rheumatology · doi:10.1093/rheumatology/kem271 · Cited by 88
Otten, M. H., Prince, F. H. M., Anink, J., Cate, R. T., Hoppenreijs, E. P. A. H., Armbrust, W., Koopman-Keemink, Y., van Pelt, P. A., Kamphuis, S. S. M., GORTER, S. L., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201060 · Cited by 61
Self-citationInterleukin-18 as a mediator of systemic juvenile idiopathic arthritis
Jelušić, M., Lukić, I. K., Tambić-Bukovac, L., Dubravčić, K., Malčić, I., Rudan, I., & Batinić, D. (2006) · Clinical Rheumatology · doi:10.1007/s10067-006-0474-0 · Cited by 49
Swart, J. F., Barug, D., Möhlmann, M., & Wulffraat, N. M. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.532785 · Cited by 42
Self-citationCytokine Multiplex Immunoassay: Methodology and (Clinical) Applications
de Jager, W., Prakken, B. J., & Rijkers, G. T. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-527-9_9 · Cited by 31
Self-citationShigeyama (2000) · doi:10.1002/1529-0131(200011)43:11
Cited by
Sota, J., Insalaco, A., Cimaz, R., Alessio, M., Cattalini, M., Gallizzi, R., Maggio, M. C., Lopalco, G., La Torre, F., Fabiani, C., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01526 · Cited by 616
Juvenile Idiopathic Arthritis: Will Etanercept be an Improvement over Current Therapies?
De Benedetti, F., & Ravelli, A. (2000) · BioDrugs · doi:10.2165/00063030-200014020-00003 · Cited by 428
Anakinra Therapy for Non-cancer Inflammatory Diseases
Cavalli, G., & Dinarello, C. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01157 · Cited by 292
Martini, A., Lovell, D. J., Albani, S., Brunner, H. I., Hyrich, K. L., Thompson, S. D., & Ruperto, N. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00332-8 · Cited by 289
Pardeo, M., Bracaglia, C., & De Benedetti, F. (2017) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2018.02.002 · Cited by 60
Metadata
- Authors
- Vastert, S. J., de Jager, W., Noordman, B. J., Holzinger, D., Kuis, W., Prakken, B. J., & Wulffraat, N. M.
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2014-03-28
- Volume
- 66
- Issue
- 4
- Pages
- 1034-1043
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W2126719354
- Cited by
- 258
- References
- 46
- FWCI
- 13.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.